CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 105 enrolled / 105 target
Drug / intervention
Not specified
Likely dose
800 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04941768
NCT04941768N/ACompletedMonitor (1.8/mo)Completion was 22mo ago
CompareCT.gov

Real-world Evaluation of Efficacy and Safety With Avelumab (BAVENCIO®) + Axitinib (INLYTA®) in Patients With aRCC in Multiple EU Countries (AVION)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·observational·Posted Jun 28, 2021·Updated Jun 16, 2026

In Brief

An observational study for Carcinoma, Renal Cell. Completed, enrolled 105 participants across 61 sites in 4 countries.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The main purpose of this study is to expand knowledge on the effectiveness of Avelumab intravenous infusion in combination with Axitinib as the first-line therapy in participants with advanced renal-cell carcinoma (aRCC) in addition to the safety and tolerability under routine conditions of daily clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Renal Cell
CountriesBelgium, Germany, Greece, Russia
CollaboratorsMerck Healthcare Germany GmbH, an affiliate of Merck KGaA, Darmstadt, Germany

Timeline

N/ACompletedFinished
20222023202420252026
First PostedJun 28, 2021
Enrollment StartAug 9, 2021
Primary CompletionAug 8, 2024
Study CompletionApr 30, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.0 years ago

Arms & Interventions

Avelumab + Axitinibother

There will not be any study-specific interventions in this study. Participants with advanced RCC receiving 800 milligrams (mg) of Avelumab intravenously every 2 weeks in combination with 5 mg of Axitinib orally twice per day in accordance with the terms of marketing authorization for the first-line therapy as per the current clinical practice will be observed for 24 months in this study.